The short version of 生长激素释放激素 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
在临床研究之外,特沙莫瑞林常被讨论为生长激素分泌促进剂,但这一说法需要限定。它并不等同于生长激素本身,也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力,另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中,尚未形成统一结论。
特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年,美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
研究背景集中在特定人群的体成分改变,尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致,部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题,现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
=== Polymorphism and temporary market withdrawal === Ritonavir was originally dispensed as a capsule that did not require refrigeration. This contained a crystal form of ritonavir that is now called form I. However, like many drugs, crystalline ritonavir can exhibit polymorphism, i.e., the same molecule can crystallize into more than one crystal type, or polymorph, each of which contains the same repeating molecule but in different crystal packings/arrangements. The solubility and hence the bioavailability can vary in the different arrangements, and this was observed for forms I and II of ritonavir. During development—ritonavir was introduced in 1996—only the crystal form now called form I was found; however, in 1998, a lower free energy, more stable polymorph, form II, was discovered. This more stable crystal form was less soluble, which resulted in significantly lower bioavailability. The compromised oral bioavailability of the drug led to temporary removal of the oral capsule formulation from the market. As a consequence of the fact that even a trace amount of form II can result in the conversion of the more bioavailable form I into form II, the presence of form II threatened the ruin of existing supplies of the oral capsule formulation of ritonavir; and indeed, form II was found in production lines, effectively halting ritonavir production. Abbott withdrew the capsules from the market, and prescribing physicians were encouraged to switch to a Norvir suspension.
=== Literature === In Western literature, vegetarianism, and topics that relate to it, have informed a "gamut of literary genres", whether literary fiction or those fictions focusing on utopias, dystopias, or apocalypses, with authors shaped by questions about human identity and "our relation to the environment", implicating vegetarianism and veganism. Others have pointed to the lack of "memorable characters" who are vegetarian. There are also vegetarian themes in horror fiction, science fiction and poetry. In 1818, Mary Shelley published the novel Frankenstein. Writer and animal rights advocate Carol J. Adams argued in her seminal book, The Sexual Politics of Meat that the unnamed creature in the novel was a vegetarian. She argued that the book was "indebted to the vegetarian climate" of its day and that vegetarianism is a major theme in the novel as a whole. She notes that the creature gives an "emotional speech" talking about its dietary principles, which makes it a "more sympathetic being" than others. She also said that it connected with Vegetarianism in the Romantic Era who believed that the Garden of Eden was meatless, rewrote the myth of Prometheus, the ideas of Jean-Jacques Rousseau, and feminist symbolism. Adams concludes that it is more likely that the "vegetarian revelations" in the novel are "silenced" due to the lack of a "framework into which we can assimilate them." Apart from Adams, scholar Suzanne Samples pointed to "gendered spaces of eating and consumption" within Victorian England which influenced literary characters of the time.
==== Malabsorption ==== Individuals with pernicious anemia do not have the ability to produce intrinsic factor. Individuals who lack intrinsic factor have no ability to absorb vitamin B12. The lack of intrinsic factor is most commonly due to autoimmune gastritis, which causes an autoimmune attack on the parietal cells that create it in the stomach. Antacid drugs that neutralize stomach acid, as well as acid-suppressing agents such as proton-pump inhibitors, can inhibit the absorption of vitamin B12 by preventing its release from food in the stomach. Other causes of B12 malabsorption include bariatric surgery, pancreatic insufficiency, obstructive jaundice, tropical sprue, celiac disease, inherited intrinsic factor deficiency, and radiation enteritis affecting the distal ileum. Age is also a contributing factor: elderly individuals are often achlorhydric due to reduced parietal cell function in the stomach, increasing their risk of vitamin B12 deficiency. The ability to absorb vitamin B12 declines with age, particularly in individuals over 60.
== Production == The series is a continuation of the series John Mulaney Presents: Everybody's in LA which ran for six episodes on Netflix as part of the Netflix is a Joke Festival in 2024. That series received both the Critics' Choice Television Award and the Television Critics Association for Outstanding Talk Series, as well as the Primetime Emmy Award for Outstanding Picture Editing for Variety Programming. The name of the series was changed from Everybody's in LA due to reactions from focus groups which showed that "people in the United States don't like Los Angeles". The show would consist of 12 episodes from March 12 to May 28, 2025, with Mulaney returning as host and Richard Kind continuing his role as side-kick and announcer. Prior to the show's premiere, Deadline Hollywood reported in January 2025 that the show was given a two-season order.
Bully: Christian Height: Weight: Fighter: Conor "Hurricane" Heun Height: 5'10 Weight: 155 lbs Victim(s): Brian and Cameron Money earned by Bully: $0 Money earned by victim(s): $10,000($5,000 each.) Original airing:
Sources: en.wikipedia.org
=== Propidium iodide === Propidium iodide is a fluorescent intercalating agent that can be used to stain cells. Propidium iodide is used as a DNA stain in flow cytometry to evaluate cell viability or DNA content in cell cycle analysis, or in microscopy to visualise the nucleus and other DNA-containing organelles. Propidium Iodide cannot cross the membrane of live cells, making it useful to differentiate necrotic, apoptotic and healthy cells. PI also binds to RNA, necessitating treatment with nucleases to distinguish between RNA and DNA staining
Under Wenger, Arsenal reached their first UEFA Champions League final in 2006 and relocated from Highbury to the Emirates Stadium. Financial constraints following the move contributed to a nine-year trophy drought, though Wenger later guided the club to further FA Cup victories in the 2010s, becoming the competition's most successful manager with seven wins. He stepped down as Arsenal manager in 2018 and retired from club management. Wenger is credited with reshaping English football culture and modernising the managerial profession, though his teams were occasionally criticised for tactical naivety and disciplinary issues. Wenger is also noted for his emphasis on youth development and talent identification throughout his career.
=== Hypothalamus === Temperature is regulated in the hypothalamus. The trigger of a fever, called a pyrogen, results in the release of prostaglandin E2 (PGE2). PGE2 in turn acts on the hypothalamus, which creates a systemic response in the body, causing heat-generating effects to match a new higher temperature set point. There are four receptors in which PGE2 can bind (EP1-4), with a previous study showing the EP3 subtype is what mediates the fever response. Hence, the hypothalamus can be seen as working like a thermostat. When the set point is raised, the body increases its temperature through both active generation of heat and retention of heat. Peripheral vasoconstriction both reduces heat loss through the skin and causes the person to feel cold. Norepinephrine increases thermogenesis in brown adipose tissue, and muscle contraction through shivering raises the metabolic rate. If these measures are insufficient to make the blood temperature in the brain match the new set point in the hypothalamus, the brain orchestrates heat effector mechanisms via the autonomic nervous system or primary motor center for shivering. These may be:
Movement demands include strength, endurance and range of motion. Training oversights occurs when the body is overused. Internally, the joints, muscles, tendons, and ligaments can affect one's flexibility. As previously mentioned, each part of the body has its own limitations and combined, the range of motion can be affected. The mental attitude of the performer during the state of motion can also affect their range.
Sources: en.wikipedia.org
== Early life and education == Frederick Sanger was born on 13 August 1918 in Rendcomb, a small village in Gloucestershire, England, the second son of Frederick Sanger, a general practitioner, and his wife, Cicely Sanger (née Crewdson). He was one of three children. His brother, Theodore, was only a year older, while his sister May (Mary) was five years younger. His father had worked as an Anglican medical missionary in China but returned to England because of ill health. He was 40 in 1916 when he married Cicely, who was four years younger. Sanger's father converted to Quakerism soon after his two sons were born and brought up the children as Quakers. Sanger's mother was the daughter of an affluent cotton manufacturer and had a Quaker background, but was not a Quaker. When Sanger was around five years old the family moved to the small village of Tanworth-in-Arden in Warwickshire. The family was reasonably wealthy and employed a governess to teach the children. In 1927, at the age of nine, he was sent to the Downs School, a residential preparatory school run by Quakers near Malvern. His brother Theo was a year ahead of him at the same school. In 1932, at the age of 14, he was sent to the recently established Bryanston School in Dorset. This used the Dalton system and had a more liberal regime which Sanger much preferred. At the school he liked his teachers and particularly enjoyed scientific subjects.
In 2020, the foundation pledged that it would divest from fossil fuel, notable since the endowment was largely funded by Standard Oil. The foundation also has a controversial past, including support of eugenics in the 1930s, as well as several scandals arising from their international field work. In 2021, the foundation's president committed to reckoning with their history, and to centering equity and inclusion.
=== February 2004 === Death in U.S. custody of chemistry professor Mohammed Munim al-Izmerly. An autopsy concluded death was caused by a sudden hit to the back of his head and that the cause of death was blunt trauma.
A positive screen warrants an antibody panel/investigation to determine if it is clinically significant. An antibody panel consists of commercially prepared group O red cell suspensions from donors that have been phenotyped for antigens that correspond to commonly encountered and clinically significant alloantibodies. Donor cells may have homozygous (e.g. K+k+), heterozygous (K+k-) expression or no expression of various antigens (K−k−). The phenotypes of all the donor cells being tested are shown in a chart. The patient's serum is tested against the various donor cells using an indirect Coombs test. Based on the reactions of the patient's serum against the donor cells, a pattern will emerge to confirm the presence of one or more antibodies. Not all antibodies are clinically significant (i.e. cause transfusion reactions, HDN, etc.). Once the patient has developed a clinically significant antibody it is vital that the patient receive antigen-negative red blood cells to prevent future transfusion reactions. If there is no antibody present, an immediate spin crossmatch may be performed where the recipient serum and donor rbc are incubated. In the immediate spin method, two drops of patient serum are tested against a drop of 3–5% suspension of donor cells in a test tube and spun in a serofuge. Agglutination or hemolysis (i.e., positive Coombs test) in the test tube is a positive reaction. If the crossmatch is positive, then further investigation is needed.
== Regulation == Use of the recombinant supplement has been controversial. The assessment of the FDA is that there is no significant difference between milk from treated and untreated cows. Twenty-one other countries have also approved marketing of rBST: Brazil, Chile, Colombia, Costa Rica, Ecuador, Egypt, Guatemala, Honduras, Jamaica, Lebanon, Mexico, Panama, Paraguay, Peru, Salvador, South Africa, South Korea, Uruguay, and Venezuela. However, regulatory bodies in several countries, such as Canada, Japan, Pakistan, Australia, New Zealand, and Argentina, along with the EU, rejected Monsanto's application to sell rBST because rBST increases the risk of health problems in cows, including mastitis, reduced fertility, and reduced body condition. In Canada, bulk milk products from the United States that have been produced with rBST are still allowed to be sold and used in food manufacture (cheese, yogurt, etc.) due to loopholes in the ingredient labelling system. The FDA, World Health Organization, and National Institutes of Health have independently stated that dairy products and meat from rBST-treated cows are safe for human consumption. In 1990, the EU placed a moratorium on its sale by all member nations. It was turned into a permanent ban starting from 1 January 2000; the decision was based solely on veterinary concerns, laws, and treaties. An in-depth report published in 1999 analysed in detail the various human health risks associated with rBST.
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称,指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽,序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良,目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化,但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.